{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T12:30:52Z","timestamp":1763037052071,"version":"3.37.3"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"GlaxoSmithKline Biologicals SA","award":["GSK study identifier: HO-14-14442"],"award-info":[{"award-number":["GSK study identifier: HO-14-14442"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Public Health"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12889-017-4064-7","type":"journal-article","created":{"date-parts":[[2017,2,2]],"date-time":"2017-02-02T00:31:10Z","timestamp":1485995470000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Health economic evaluation of Human Papillomavirus vaccines in women from Venezuela by a lifetime Markov cohort model"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4437-0073","authenticated-orcid":false,"given":"Ariel Esteban","family":"Bardach","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osvaldo Ulises","family":"Garay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"Calder\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9s","family":"Pich\u00f3n-Rivi\u00e9re","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico","family":"Augustovski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebasti\u00e1n Garc\u00eda","family":"Mart\u00ed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula","family":"Corti\u00f1as","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marino","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura T.","family":"Naranjo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge Alberto","family":"Gomez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joaqu\u00edn Enzo","family":"Caporale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,2,2]]},"reference":[{"issue":"37","key":"4064_CR1","doi-asserted-by":"crossref","first-page":"3962","DOI":"10.1016\/j.vaccine.2013.06.008","volume":"31","author":"N Demarteau","year":"2013","unstructured":"Demarteau N, Van Kriekinge G, Simon P. Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium. Vaccine. 2013;31(37):3962\u201371.","journal-title":"Vaccine"},{"issue":"6","key":"4064_CR2","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1590\/S1020-49892012000600007","volume":"31","author":"CM Pierce Campbell","year":"2012","unstructured":"Pierce Campbell CM, Curado MP, Harlow SD, Soliman AS. Variation of cervical cancer incidence in Latin America and the Caribbean. Rev Panam Salud Publica. 2012;31(6):492\u20138.","journal-title":"Rev Panam Salud Publica"},{"issue":"Suppl 3","key":"4064_CR3","first-page":"S306","volume":"45","author":"S Arrossi","year":"2003","unstructured":"Arrossi S, Sankaranarayanan R, Parkin DM. Incidence and mortality of cervical cancer in Latin America. Salud Publica Mex. 2003;45 Suppl 3:S306\u201314.","journal-title":"Salud Publica Mex"},{"key":"4064_CR4","unstructured":"XIV National Census of Population and Housing. In. Bolivarian Republic of Venezuela: National Institute of Statistics 2011."},{"key":"4064_CR5","unstructured":"Human Papillomavirus and Related Disease Report. Venezuela. In.: WHO\/ICO Information Centre on Human Papilloma Virus (HPV) and Cervical Cancer; 2013."},{"key":"4064_CR6","unstructured":"National Mortality Yearbook 2011. In. Bolivarian Republic of Venezuela: Ministry of Health.; 2014: 389."},{"issue":"4","key":"4064_CR7","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.otpol.2014.05.004","volume":"68","author":"M Wierzbicka","year":"2014","unstructured":"Wierzbicka M, Jozefiak A, Jackowska J, Szydlowski J, Gozdzicka-Jozefiak A. HPV vaccination in head and neck HPV-related pathologies. Otolaryngol Pol. 2014;68(4):157\u201373.","journal-title":"Otolaryngol Pol"},{"issue":"9","key":"4064_CR8","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1007\/s11912-014-0402-4","volume":"16","author":"K Wakeham","year":"2014","unstructured":"Wakeham K, Kavanagh K. The burden of HPV-associated anogenital cancers. Curr Oncol Rep. 2014;16(9):402.","journal-title":"Curr Oncol Rep"},{"issue":"4","key":"4064_CR9","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1128\/JCM.33.4.901-905.1995","volume":"33","author":"MV Jacobs","year":"1995","unstructured":"Jacobs MV, de Roda Husman AM, van den Brule AJ, Snijders PJ, Meijer CJ, Walboomers JM. Group-specific differentiation between high- and low-risk human papillomavirus genotypes by general primer-mediated PCR and two cocktails of oligonucleotide probes. J Clin Microbiol. 1995;33(4):901\u20135.","journal-title":"J Clin Microbiol"},{"issue":"1-2","key":"4064_CR10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1386-6532(00)00125-6","volume":"19","author":"N Munoz","year":"2000","unstructured":"Munoz N. Human papillomavirus and cancer: the epidemiological evidence. J Clin Virol. 2000;19(1-2):1\u20135.","journal-title":"J Clin Virol"},{"issue":"4","key":"4064_CR11","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1136\/jcp.55.4.244","volume":"55","author":"FX Bosch","year":"2002","unstructured":"Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol. 2002;55(4):244\u201365.","journal-title":"J Clin Pathol"},{"issue":"5-6","key":"4064_CR12","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1159\/000214927","volume":"12","author":"N Munoz","year":"2009","unstructured":"Munoz N. From causality to prevention - the example of cervical cancer: my personal contribution to this fascinating history. Public Health Genomics. 2009;12(5-6):368\u201371.","journal-title":"Public Health Genomics"},{"issue":"1","key":"4064_CR13","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F","volume":"189","author":"JM Walboomers","year":"1999","unstructured":"Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189(1):12\u20139.","journal-title":"J Pathol"},{"issue":"3","key":"4064_CR14","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.ygyno.2011.02.003","volume":"121","author":"M Correnti","year":"2011","unstructured":"Correnti M, Medina F, Cavazza ME, Rennola A, Avila M, Fernandes A. Human papillomavirus (HPV) type distribution in cervical carcinoma, low-grade, and high-grade squamous intraepithelial lesions in Venezuelan women. Gynecol Oncol. 2011;121(3):527\u201331.","journal-title":"Gynecol Oncol"},{"issue":"5","key":"4064_CR15","doi-asserted-by":"crossref","first-page":"e284","DOI":"10.1016\/j.canep.2012.04.005","volume":"36","author":"J Sanchez-Lander","year":"2012","unstructured":"Sanchez-Lander J, Cortinas P, Loureiro CL, Pujol FH, Medina F, Capote-Negrin L, Bianchi G, Garcia-Barriola V, Ruiz-Benni A, Avilan-Rovira J, et al. Human papillomavirus in invasive cervical cancer and cervical intraepithelial neoplasia 2 and 3 in Venezuela: a cross-sectional study. Cancer Epidemiol. 2012;36(5):e284\u20137.","journal-title":"Cancer Epidemiol"},{"key":"4064_CR16","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3389\/fonc.2014.00020","volume":"4","author":"P Giorgi Rossi","year":"2014","unstructured":"Giorgi Rossi P, Baldacchini F, Ronco G. The Possible Effects on Socio-Economic Inequalities of Introducing HPV Testing as Primary Test in Cervical Cancer Screening Programs. Frontiers Oncol. 2014;4:20.","journal-title":"Frontiers Oncol"},{"issue":"4","key":"4064_CR17","doi-asserted-by":"crossref","first-page":"187","DOI":"10.4103\/2278-330X.119877","volume":"2","author":"P Basu","year":"2013","unstructured":"Basu P, Banerjee D, Singh P, Bhattacharya C, Biswas J. Efficacy and safety of human papillomavirus vaccine for primary prevention of cervical cancer: A review of evidence from phase III trials and national programs. South Asian J Cancer. 2013;2(4):187\u201392.","journal-title":"South Asian J Cancer"},{"issue":"5","key":"4064_CR18","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.jval.2012.02.012","volume":"15","author":"N Demarteau","year":"2012","unstructured":"Demarteau N, Tang CH, Chen HC, Chen CJ, Van Kriekinge G. Cost-effectiveness analysis of the bivalent compared with the quadrivalent human papillomavirus vaccines in Taiwan. Value Health. 2012;15(5):622\u201331.","journal-title":"Value Health"},{"issue":"22","key":"4064_CR19","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1093\/jnci\/djs395","volume":"104","author":"N Velde Van de","year":"2012","unstructured":"Van de Velde N, Boily MC, Drolet M, Franco EL, Mayrand MH, Kliewer EV, Coutlee F, Laprise JF, Malagon T, Brisson M. Population-level impact of the bivalent, quadrivalent, and nonavalent human papillomavirus vaccines: a model-based analysis. J Natl Cancer Inst. 2012;104(22):1712\u201323.","journal-title":"J Natl Cancer Inst"},{"key":"4064_CR20","doi-asserted-by":"crossref","first-page":"999","DOI":"10.2147\/IJWH.S50365","volume":"6","author":"R Vincenzo De","year":"2014","unstructured":"De Vincenzo R, Conte C, Ricci C, Scambia G, Capelli G. Long-term efficacy and safety of human papillomavirus vaccination. Int J Women\u2019s Health. 2014;6:999\u20131010.","journal-title":"Int J Women\u2019s Health"},{"issue":"Suppl 11","key":"4064_CR21","doi-asserted-by":"crossref","first-page":"L37","DOI":"10.1016\/j.vaccine.2008.06.013","volume":"26","author":"R Murillo","year":"2008","unstructured":"Murillo R, Almonte M, Pereira A, Ferrer E, Gamboa OA, Jeronimo J, Lazcano-Ponce E. Cervical cancer screening programs in Latin America and the Caribbean. Vaccine. 2008;26 Suppl 11:L37\u201348.","journal-title":"Vaccine"},{"issue":"40","key":"4064_CR22","doi-asserted-by":"crossref","first-page":"5519","DOI":"10.1016\/j.vaccine.2009.06.097","volume":"27","author":"L Colantonio","year":"2009","unstructured":"Colantonio L, Gomez JA, Demarteau N, Standaert B, Pichon-Riviere A, Augustovski F. Cost-effectiveness analysis of a cervical cancer vaccine in five Latin American countries. Vaccine. 2009;27(40):5519\u201329.","journal-title":"Vaccine"},{"issue":"8","key":"4064_CR23","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1093\/jnci\/djh104","volume":"96","author":"SJ Goldie","year":"2004","unstructured":"Goldie SJ, Kohli M, Grima D, Weinstein MC, Wright TC, Bosch FX, Franco E. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16\/18 vaccine. J Natl Cancer Inst. 2004;96(8):604\u201315.","journal-title":"J Natl Cancer Inst"},{"issue":"Suppl 5","key":"4064_CR24","doi-asserted-by":"crossref","first-page":"F29","DOI":"10.1016\/j.vaccine.2008.05.069","volume":"26","author":"E Suarez","year":"2008","unstructured":"Suarez E, Smith JS, Bosch FX, Nieminen P, Chen CJ, Torvinen S, Demarteau N, Standaert B. Cost-effectiveness of vaccination against cervical cancer: a multi-regional analysis assessing the impact of vaccine characteristics and alternative vaccination scenarios. Vaccine. 2008;26 Suppl 5:F29\u201345.","journal-title":"Vaccine"},{"key":"4064_CR25","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1186\/1471-2458-9-401","volume":"9","author":"AM Anonychuk","year":"2009","unstructured":"Anonychuk AM, Bauch CT, Merid MF, Van Kriekinge G, Demarteau N. A cost-utility analysis of cervical cancer vaccination in preadolescent Canadian females. BMC Public Health. 2009;9:401.","journal-title":"BMC Public Health"},{"issue":"Suppl 5","key":"4064_CR26","doi-asserted-by":"crossref","first-page":"F16","DOI":"10.1016\/j.vaccine.2008.02.040","volume":"26","author":"D Debicki","year":"2008","unstructured":"Debicki D, Ferko N, Demarteau N, Gallivan S, Bauch C, Anonychuk A, Mantovani L, Capri S, Chou CY, Standaert B, et al. Comparison of detailed and succinct cohort modelling approaches in a multi-regional evaluation of cervical cancer vaccination. Vaccine. 2008;26 Suppl 5:F16\u201328.","journal-title":"Vaccine"},{"issue":"2","key":"4064_CR27","doi-asserted-by":"crossref","first-page":"324","DOI":"10.3111\/13696998.2010.490481","volume":"13","author":"N Demarteau","year":"2010","unstructured":"Demarteau N, Standaert B. Modelling the economic value of cross- and sustained-protection in vaccines against cervical cancer. J Med Econ. 2010;13(2):324\u201338.","journal-title":"J Med Econ"},{"key":"4064_CR28","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1186\/1471-2458-14-1222","volume":"14","author":"JA Gomez","year":"2014","unstructured":"Gomez JA, Lepetic A, Demarteau N. Health economic analysis of human papillomavirus vaccines in women of Chile: perspective of the health care payer using a Markov model. BMC Public Health. 2014;14:1222.","journal-title":"BMC Public Health"},{"issue":"2","key":"4064_CR29","first-page":"203","volume":"50","author":"J N\u00fa\u00f1ez-Troconis","year":"2009","unstructured":"N\u00fa\u00f1ez-Troconis J, Delgado M, Gonz\u00e1lez J, Mindiola R, Vel\u00e1squez J, Conde B, Whitby D, Munroe DJ. Prevalence and risk factors of human papillomavirus infection in asymptomatic women in a Venezuelan urban area. Invest cl\u00edn. 2009;50(2):203\u201312.","journal-title":"Invest cl\u00edn"},{"issue":"12","key":"4064_CR30","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1158\/1055-9965.2271.13.12","volume":"13","author":"C Ferreccio","year":"2004","unstructured":"Ferreccio C, Prado RB, Luzoro AV, Ampuero SL, Snijders PJ, Meijer CJ, Vaccarella SV, Jara AT, Puschel KI, Robles SC, et al. Population-based prevalence and age distribution of human papillomavirus among women in Santiago, Chile. Cancer Epidemiol Biomarkers Prev. 2004;13(12):2271\u20136.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"4064_CR31","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1186\/1471-2334-10-360","volume":"10","author":"AA Kraut","year":"2010","unstructured":"Kraut AA, Schink T, Schulze-Rath R, Mikolajczyk RT, Garbe E. Incidence of anogenital warts in Germany: a population-based cohort study. BMC Infect Dis. 2010;10:360.","journal-title":"BMC Infect Dis"},{"issue":"7","key":"4064_CR32","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.puhe.2011.01.016","volume":"125","author":"CD Scarbrough Lefebvre","year":"2011","unstructured":"Scarbrough Lefebvre CD, Van Kriekinge G, Goncalves MA, de Sanjose S. Appraisal of the burden of genital warts from a healthcare and individual patient perspective. Public Health. 2011;125(7):464\u201375.","journal-title":"Public Health"},{"key":"4064_CR33","first-page":"127","volume":"28","author":"M Avila","year":"2008","unstructured":"Avila M, Cavazza M, Vasquez W, Ortega J, Lopez Y, Correnti M. Genotipificaci\u00f3n del virus de papiloma humano en pacientes con condilomas acuminados. Rev Soc Venez Microbiol. 2008;28:127\u201333.","journal-title":"Rev Soc Venez Microbiol"},{"issue":"5","key":"4064_CR34","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.bpobgyn.2011.04.007","volume":"25","author":"KU Petry","year":"2011","unstructured":"Petry KU. Management options for cervical intraepithelial neoplasia. Best Pract Res Clin Obstet Gynaecol. 2011;25(5):641\u201351.","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"issue":"10","key":"4064_CR35","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1093\/jnci\/djp089","volume":"101","author":"J Melnikow","year":"2009","unstructured":"Melnikow J, McGahan C, Sawaya GF, Ehlen T, Coldman A. Cervical intraepithelial neoplasia outcomes after treatment: long-term follow-up from the British Columbia Cohort Study. J Natl Cancer Inst. 2009;101(10):721\u20138.","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"4064_CR36","first-page":"81","volume":"68","author":"A Rodr\u00edguez","year":"2008","unstructured":"Rodr\u00edguez A, Santos M, Noguera M, Romero L. Seguimiento y sobrevida de pacientes con carcinoma invasor del cuello uterino. Rev Obstet Ginecol Venez. 2008;68(2):81\u20136.","journal-title":"Rev Obstet Ginecol Venez"},{"key":"4064_CR37","unstructured":"Official Standard for Comprehensive Sexual and Reproductive Health..In. Bolivarian Republic of Venezuela: Ministry of Health; 2013."},{"issue":"2","key":"4064_CR38","first-page":"102","volume":"23","author":"F Medina","year":"2010","unstructured":"Medina F, Sanchez-Lander J, Calderaro F, Borges A. Cancer de Cuello Uterino. Consenso Nacional para el Diagnostico y Tratamiento. Rev Venez Oncol 2011. 2010;23(2):102\u201329.","journal-title":"Rev Venez Oncol 2011"},{"key":"4064_CR39","unstructured":"Public Tariff of services. In. Caracas, Venezuela: Official Journal of Bolivarian Republic of Venezuela; 2013."},{"key":"4064_CR40","volume-title":"I Encuesta Nacional de Salud. Venezuela 2011. Resultados: preguntas de cobertura de seguros","author":"MRE Gonzalez","year":"2013","unstructured":"Gonzalez MRE, Mijares R. I Encuesta Nacional de Salud. Venezuela 2011. Resultados: preguntas de cobertura de seguros. Caracas: FUNINDES-USB, Unidad de Pol\u00edticas P\u00fablicas; 2013."},{"key":"4064_CR41","unstructured":"Insituto Nacional de Estad\u00edstica, Rep\u00fablica Bolivariana de Venezuela. Indice Nacional de Precios al Consumidor [ http:\/\/www.ine.gov.ve\/index.php?option=com_content&view=category&id=108&Itemid=62 Accessed Dec 2015]"},{"key":"4064_CR42","unstructured":"Pan American Health Organization: PAHO Revolving Fund. Vaccine prices. 2013. http:\/\/www.paho.org\/hq\/index.php?option=com_content&view=article&id=1864%3A2014-paho-revolving-fund&catid=839%3Arevolving-fund&Itemid=4135&lang=en Accessed 24 July 2015."},{"issue":"9686","key":"4064_CR43","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0140-6736(09)61248-4","volume":"374","author":"J Paavonen","year":"2009","unstructured":"Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow SN, Apter D, Kitchener H, Castellsague X, Teixeira JC, Skinner SR, et al. Efficacy of human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet. 2009;374(9686):301\u201314.","journal-title":"Lancet"},{"issue":"9706","key":"4064_CR44","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1016\/S0140-6736(09)61567-1","volume":"374","author":"B Romanowski","year":"2009","unstructured":"Romanowski B, de Borba PC, Naud PS, Roteli-Martins CM, De Carvalho NS, Teixeira JC, Aoki F, Ramjattan B, Shier RM, Somani R, et al. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4\u00a0years. Lancet. 2009;374(9706):1975\u201385.","journal-title":"Lancet"},{"issue":"19","key":"4064_CR45","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1056\/NEJMoa061741","volume":"356","author":"Future II Study Group","year":"2007","unstructured":"Future II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356(19):1915\u201327.","journal-title":"N Engl J Med"},{"issue":"7","key":"4064_CR46","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1086\/597307","volume":"199","author":"DR Brown","year":"2009","unstructured":"Brown DR, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, Koutsky LA, Tay EH, Garcia P, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis. 2009;199(7):926\u201335.","journal-title":"J Infect Dis"},{"key":"4064_CR47","unstructured":"Skinner SR AD, Chow SN, Wheeler C, Dubin G; for the HPV PATRICIA Study Group,: International Papillomavirus Conference and Clinical Workshop, Malm\u00f6, 2009. Cross-protective efficacy of Cervarix\u2122 against oncogenic hpv types beyond hpv-16\/18: final analysis of cross-protection - PATRICIA study. Page 67\/69. 2009."},{"issue":"3","key":"4064_CR48","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1517\/14712591003601944","volume":"10","author":"A Szarewski","year":"2010","unstructured":"Szarewski A. HPV vaccine: Cervarix. Expert Opin Biol Ther. 2010;10(3):477\u201387.","journal-title":"Expert Opin Biol Ther"},{"key":"4064_CR49","unstructured":"Tjalma W. 16th International meeting of the European Society of Gynaecological Oncology (ESGO). Serbia: Belgrade; 2009. Efficacy of the HPV-16\/18 AS04-adjuvanted vaccine against abnormal cytology and low-grade histopathological lesions in an oncogenic HPV-na\u00efve population."},{"issue":"1","key":"4064_CR50","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S1470-2045(11)70287-X","volume":"13","author":"CM Wheeler","year":"2012","unstructured":"Wheeler CM, Castellsague X, Garland SM, Szarewski A, Paavonen J, Naud P, Salmeron J, Chow SN, Apter D, Kitchener H, et al. Cross-protective efficacy of HPV-16\/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 2012;13(1):100\u201310.","journal-title":"Lancet Oncol"},{"issue":"32","key":"4064_CR51","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/S0968-8080(08)32409-4","volume":"16","author":"SJ Goldie","year":"2008","unstructured":"Goldie SJ, O\u2019Shea M, Diaz M, Kim SY. Benefits, cost requirements and cost-effectiveness of the HPV16,18 vaccine for cervical cancer prevention in developing countries: policy implications. Reprod Health Matters. 2008;16(32):86\u201396.","journal-title":"Reprod Health Matters"},{"key":"4064_CR52","doi-asserted-by":"crossref","unstructured":"Romanowski B, Schwarz TF, Ferguson L, Peters K, Dionne M, Behre U, Schulze K, Hillemanns P, Suryakiran P, Thomas F, et al. Sustained immunogenicity of the HPV-16\/18 AS04-adjuvanted vaccine administered as a two-dose schedule in adolescent girls: Five-year clinical data and modeling predictions from a randomized study. Hum Vaccines Immunotherapeut. 2015;1\u201310.","DOI":"10.1080\/21645515.2015.1065363"},{"issue":"1","key":"4064_CR53","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.vaccine.2012.09.037","volume":"31","author":"AB Moscicki","year":"2012","unstructured":"Moscicki AB, Wheeler CM, Romanowski B, Hedrick J, Gall S, Ferris D, Poncelet S, Zahaf T, Moris P, Geeraerts B, et al. Immune responses elicited by a fourth dose of the HPV-16\/18 AS04-adjuvanted vaccine in previously vaccinated adult women. Vaccine. 2012;31(1):234\u201341.","journal-title":"Vaccine"},{"issue":"19","key":"4064_CR54","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1093\/jnci\/djr319","volume":"103","author":"AR Kreimer","year":"2011","unstructured":"Kreimer AR, Rodriguez AC, Hildesheim A, Herrero R, Porras C, Schiffman M, Gonzalez P, Solomon D, Jimenez S, Schiller JT, et al. Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16\/18 vaccine. J Natl Cancer Inst. 2011;103(19):1444\u201351.","journal-title":"J Natl Cancer Inst"},{"key":"4064_CR55","unstructured":"Puthanakit T, Huang L, Tang R, Schwarz T, Esposito S, Frenette L, McNeil S, Rheault P, Horn M, Klar M. Paediatric Infectious Diseases Meeting. Dublin, Ireland. Non-Inferiority of HPV -16\/18 AS04-adjuvanted vaccine administered as 2-dose chedules in girls (9\u201314 years) versus 3 doses in women (15\u201325 years): A randomised controlled trial..In.; 2014."},{"issue":"5","key":"4064_CR56","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.4161\/hv.28022","volume":"10","author":"B Romanowski","year":"2014","unstructured":"Romanowski B, Schwarz TF, Ferguson LM, Ferguson M, Peters K, Dionne M, Schulze K, Ramjattan B, Hillemanns P, Behre U, et al. Immune response to the HPV-16\/18 AS04-adjuvanted vaccine administered as a 2-dose or 3-dose schedule up to 4\u00a0years after vaccination: results from a randomized study. Human Vaccines Immunotherapeutics. 2014;10(5):1155\u201365.","journal-title":"Human Vaccines Immunotherapeutics"},{"issue":"12","key":"4064_CR57","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.4161\/hv.7.12.18322","volume":"7","author":"B Romanowski","year":"2011","unstructured":"Romanowski B, Schwarz TF, Ferguson LM, Peters K, Dionne M, Schulze K, Ramjattan B, Hillemanns P, Catteau G, Dobbelaere K, et al. Immunogenicity and safety of the HPV-16\/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized study. Human vaccines. 2011;7(12):1374\u201386.","journal-title":"Human vaccines"},{"key":"4064_CR58","doi-asserted-by":"crossref","unstructured":"Hernandez-Avila M, Torres-Ibarra L, Stanley M, Salmeron J, Cruz-Valdez A, Munoz N, Herrero R, Villasenor-Ruiz IF, Lazcano-Ponce E. Evaluation of the immunogenicity of the quadrivalent HPV vaccine using 2 versus 3 doses at month 21: An epidemiological surveillance mechanism for alternate vaccination schemes. Human Vaccines Immunotherapeutics. 2015;1\u20139.","DOI":"10.1080\/21645515.2015.1058458"},{"issue":"5","key":"4064_CR59","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1586\/erp.10.56","volume":"10","author":"F Augustovski","year":"2010","unstructured":"Augustovski F, Garay OU, Pichon-Riviere A, Rubinstein A, Caporale JE. Economic evaluation guidelines in Latin America: a current snapshot. Expert Rev Pharmacoecon Outcomes Res. 2010;10(5):525\u201337.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"4064_CR60","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/1471-2334-9-119","volume":"9","author":"RP Insinga","year":"2009","unstructured":"Insinga RP, Dasbach EJ, Elbasha EH. Epidemiologic natural history and clinical management of Human Papillomavirus (HPV) Disease: a critical and systematic review of the literature in the development of an HPV dynamic transmission model. BMC Infect Dis. 2009;9:119.","journal-title":"BMC Infect Dis"},{"key":"4064_CR61","doi-asserted-by":"crossref","unstructured":"Briggs A SM, Claxton K. Decision Modelling for Health Economic Evaluation. Handbooks in Health Economic Evaluation. Oxford University Press 2006.","DOI":"10.1093\/oso\/9780198526629.001.0001"},{"issue":"8","key":"4064_CR62","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1002\/hec.635","volume":"10","author":"E Fenwick","year":"2001","unstructured":"Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Econ. 2001;10(8):779\u201387.","journal-title":"Health Econ"},{"key":"4064_CR63","volume-title":"GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11[Internet]","author":"J Ferlay","year":"2013","unstructured":"Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin D, Forman D, Bray F. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11[Internet]. Lyon: International Agency for Research on Cancer; 2013."},{"issue":"2","key":"4064_CR64","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s00038-010-0216-6","volume":"56","author":"N Demarteau","year":"2011","unstructured":"Demarteau N, Detournay B, Tehard B, El Hasnaoui A, Standaert B. A generally applicable cost-effectiveness model for the evaluation of vaccines against cervical cancer. Int J Public Health. 2011;56(2):153\u201362.","journal-title":"Int J Public Health"},{"issue":"6","key":"4064_CR65","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1136\/sextrans-2011-050073","volume":"87","author":"SC Woodhall","year":"2011","unstructured":"Woodhall SC, Jit M, Soldan K, Kinghorn G, Gilson R, Nathan M, Ross JD, Lacey CJ. The impact of genital warts: loss of quality of life and cost of treatment in eight sexual health clinics in the UK. Sex Transm Infect. 2011;87(6):458\u201363.","journal-title":"Sex Transm Infect"},{"issue":"19","key":"4064_CR66","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1056\/NEJMoa061760","volume":"356","author":"SM Garland","year":"2007","unstructured":"Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, Tang GW, Ferris DG, Steben M, Bryan J, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007;356(19):1928\u201343.","journal-title":"N Engl J Med"},{"issue":"5","key":"4064_CR67","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/jnci\/djp534","volume":"102","author":"N Munoz","year":"2010","unstructured":"Munoz N, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, Brown DR, Koutsky LA, Tay EH, et al. Impact of human papillomavirus (HPV)-6\/11\/16\/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst. 2010;102(5):325\u201339.","journal-title":"J Natl Cancer Inst"},{"key":"4064_CR68","unstructured":"The World Bank. World Development Indicator Database [Available at: http:\/\/data.worldbank.org\/indicator\/NY.GDP.PCAP.CN .]"}],"container-title":["BMC Public Health"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-017-4064-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,22]],"date-time":"2024-06-22T06:12:59Z","timestamp":1719036779000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcpublichealth.biomedcentral.com\/articles\/10.1186\/s12889-017-4064-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,2]]},"references-count":68,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["4064"],"URL":"https:\/\/doi.org\/10.1186\/s12889-017-4064-7","relation":{},"ISSN":["1471-2458"],"issn-type":[{"type":"electronic","value":"1471-2458"}],"subject":[],"published":{"date-parts":[[2017,2,2]]},"article-number":"152"}}